480 related articles for article (PubMed ID: 31726765)
1. Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction.
Wakisaka M; Kamouchi M; Kitazono T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31726765
[TBL] [Abstract][Full Text] [Related]
2. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ; Johnson EJ; Tuttle KR
Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
[TBL] [Abstract][Full Text] [Related]
5. Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies.
Takada S; Sabe H; Kinugawa S
Am J Physiol Heart Circ Physiol; 2022 Feb; 322(2):H117-H128. PubMed ID: 34860594
[TBL] [Abstract][Full Text] [Related]
6. Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System.
Poursharif S; Hamza S; Braam B
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232506
[TBL] [Abstract][Full Text] [Related]
7. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Packer M; Anker SD; Butler J; Filippatos G; Zannad F
JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
Kawanami D; Matoba K; Takeda Y; Nagai Y; Akamine T; Yokota T; Sango K; Utsunomiya K
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524098
[TBL] [Abstract][Full Text] [Related]
9. The presence of sodium glucose co-transporter 2 in mesangial cells and pericytes and its roles in mesangial lesions and in capillaries under diabetic and ischemic conditions.
Wakisaka M; Nakamura K; Kitazono T
Diabetes Res Clin Pract; 2022 Oct; 192():110096. PubMed ID: 36174778
[TBL] [Abstract][Full Text] [Related]
10. A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion.
Kuriyama S
Kidney Blood Press Res; 2019; 44(4):449-456. PubMed ID: 31291624
[TBL] [Abstract][Full Text] [Related]
11. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
[TBL] [Abstract][Full Text] [Related]
12. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.
Wang L; Cai Y; Jian L; Cheung CW; Zhang L; Xia Z
Cardiovasc Diabetol; 2021 Jan; 20(1):2. PubMed ID: 33397369
[TBL] [Abstract][Full Text] [Related]
13. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy.
Li N; Zhou H
Drug Des Devel Ther; 2020; 14():4775-4788. PubMed ID: 33192053
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
[TBL] [Abstract][Full Text] [Related]
17. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves.
Katsurada K; Nandi SS; Sharma NM; Patel KP
Circ Heart Fail; 2021 Dec; 14(12):e008365. PubMed ID: 34789005
[TBL] [Abstract][Full Text] [Related]
19. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
Prandi FR; Barone L; Lecis D; Belli M; Sergi D; Milite M; Lerakis S; Romeo F; Barillà F
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291558
[TBL] [Abstract][Full Text] [Related]
20. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
